KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacific Biosciences Of California (PACB) Cash & Equivalents (2016 - 2026)

Pacific Biosciences Of California has reported Cash & Equivalents over the past 16 years, most recently at $63.7 million for Q4 2025.

  • For Q4 2025, Cash & Equivalents rose 15.06% year-over-year to $63.7 million; the TTM value through Dec 2025 reached $63.7 million, up 15.06%, while the annual FY2025 figure was $63.7 million, 15.06% up from the prior year.
  • Cash & Equivalents for Q4 2025 was $63.7 million at Pacific Biosciences Of California, up from $56.5 million in the prior quarter.
  • Over five years, Cash & Equivalents peaked at $932.4 million in Q1 2021 and troughed at $54.8 million in Q2 2025.
  • A 5-year average of $257.5 million and a median of $209.3 million in 2023 define the central range for Cash & Equivalents.
  • Biggest five-year swings in Cash & Equivalents: soared 1254.01% in 2021 and later crashed 79.78% in 2024.
  • Year by year, Cash & Equivalents stood at $460.7 million in 2021, then dropped by 29.44% to $325.1 million in 2022, then plummeted by 44.66% to $179.9 million in 2023, then tumbled by 69.22% to $55.4 million in 2024, then rose by 15.06% to $63.7 million in 2025.
  • Business Quant data shows Cash & Equivalents for PACB at $63.7 million in Q4 2025, $56.5 million in Q3 2025, and $54.8 million in Q2 2025.